Descripción
This is NTNU NTNU is a broad-based university with a technical-scientific profile and a focus in professional education. The university is located in three cities with headquarters in Trondheim. At NTNU, 9,000 employees and 43,000 students work to create knowledge for a better world. You can find more information about working at NTNU and the application process here. Video: https://youtu.be/Xt-yHCN5QS0 About the Job Are you excited by the possibility of turning cellular imaging, drug-response data and cancer biology into better treatment predictions for individual patients? We have a two-year position for a researcher in computational high-content imaging analysis as part of the international EP PerMed project ERKetype. ERKetype aims to develop digital twins as complex biomarkers for precision cancer medicine, with a particular focus on cancers driven by dysregulation of the RAS/RAF/MEK/ERK signalling pathway. The project combines patient-derived cancer models, Cell Painting and other high-content imaging approaches, pharmaco-proteomics, multi-omics data, artificial intelligence and mechanism-based modelling to understand why cancer cells respond — or fail to respond — to targeted therapies. The researcher will be part of FlobakLab at NTNU (www.flobaklab.com), an interdisciplinary precision oncology group with expertise in both wet- and dry-lab research. In this position, you will play a central role in analysing Cell Painting and high-content imaging data from drug screens in cancer cell lines, patient-derived cancer organoids and patient-derived tumouroids. You will work closely with SINTEF Industry and its robotic high-throughput drug-screening facilities. The researcher will also have access to FlobakLab’s dedicated GPU workstation, equipped with 4 × RTX PRO 6000 Max-Q GPUs and supported by NVIDIA. Your work will include developing reproducible Python-based analysis pipelines, extracting and interpreting morphological drug-response signatures, and developing an